CTOs on the Move

Xilio Therapeutics

www.xiliotx.com

 
Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company`s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.xiliotx.com
  • 828 Winter Street
    Waltham, MA USA 02451
  • Phone: 617.833.1027

Executives

Name Title Contact Details
Li Malmberg
 Chief Technology and Manufacturing Officer Profile

Funding

Xilio Therapeutics raised $100M on 03/02/2020
Xilio Therapeutics raised $95M on 02/24/2021

Similar Companies

Provident Clinical Research and Consulting

Provident Clinical Research and Consulting is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellular Technology

Cellular Technology is a Beachwood, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boston Biomedical Research Institute

The Boston Biomedical Research Institute (BBRI) is dedicated to basic biomedical research to promote the understanding, treatment and prevention of specific human diseases. The areas of investigation concern the structure and function of muscle proteins,

Neuron23

Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.

Imvax

The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.